August 26, 2020
RFA AG-21-026 - Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed)
National Institute on Aging (NIA)
This Notice informs potential applicants of the following changes to RFA AG-21-026 - Preclinical Development of Novel Therapeutics Targeting Aging Mechanisms (SBIR U44 Clinical Trial Not Allowed):
Current language:
Part 2. Full Text of Announcement
Section IV. Application and Submission Information
2. Content and Form of Application Submission
Page Limitations
All page limitations described in the SF424 (R&R) SBIR/STTR Application Guide and the Table of Page Limits must be followed.
Modified to read:
Part 2. Full Text of Announcement
Section IV. Application and Submission Information
2. Content and Form of Application Submission
Page Limitations
All page limitations described in the SF424 (R&R) SBIR/STTR Application Guide and the Table of Page Limits must be followed, with the following exception: The page limit for the Research Strategy section is 30 pages.
All other aspects of this FOA remain unchanged.
Inquiries regarding the scientific scope of the applications may be directed to:
Chhanda Dutta, Ph.D
National Institute on Aging (NIA)
Telephone: 301-496-4161
Email: duttac@mail.nih.gov
Rebecca Fuldner, Ph.D.
Division of Aging Biology
National Institute on Aging (NIA)
Telephone: 301-496-6402
Email: Fuldnerr@mail.nih.gov
Inquiries specific to the NIA small business research program should be directed to:
Todd Haim, Ph.D.
Office of Small Business Research
National Institute on Aging (NIA)
Telephone: 301-480-7867
Email: Todd.Haim@nih.gov